Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Other Accumulated Expenses (2016 - 2026)

Seres Therapeutics (MCRB) has disclosed Other Accumulated Expenses for 11 consecutive years, with $896000.0 as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 58.58% to $896000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $896000.0 through Dec 2025, down 58.58% year-over-year, with the annual reading at $896000.0 for FY2025, 58.58% down from the prior year.
  • Other Accumulated Expenses hit $896000.0 in Q4 2025 for Seres Therapeutics, down from $1.5 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $8.0 million in Q2 2023 to a low of $896000.0 in Q4 2025.
  • Historically, Other Accumulated Expenses has averaged $3.2 million across 5 years, with a median of $2.7 million in 2023.
  • Biggest five-year swings in Other Accumulated Expenses: soared 348.03% in 2023 and later plummeted 77.38% in 2025.
  • Year by year, Other Accumulated Expenses stood at $3.6 million in 2021, then grew by 0.3% to $3.6 million in 2022, then decreased by 23.93% to $2.8 million in 2023, then dropped by 21.97% to $2.2 million in 2024, then crashed by 58.58% to $896000.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for MCRB at $896000.0 in Q4 2025, $1.5 million in Q3 2025, and $1.0 million in Q2 2025.